Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective

• Główni autorzy: Shah D (Autor), Risebrough NA (Autor), Perdrizet J (Autor), Iyer NN (Autor), Gamble C (Autor), Dang-Tan T (Autor)
• Format: Książka
• Wydane: Dove Medical Press, 2018-11-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Dhvani Shah,1 Nancy A Risebrough,2 Johnna Perdrizet,1 Neeraj N Iyer,3 Cory Gamble,4 Tam Dang-Tan3 1ICON, Commercialisation and Outcomes, Health Economics, New York, NY, USA; 2ICON, Commercialisation and Outcomes, Health Economics, Toronto, ON, Canada; 3HEOR & Data Analytics, Novo Nordisk Inc, Pl...